XOMA : Analysis & Opinions
October 20, 2016Xoma received preliminary approval to initiate a Phase 2 clinical study of its Xoma 358 drug to treat children over age 2 ...
October 17, 2016Xoma declared a 1-for-20 reverse stock split to comply with the $1 per share minimum bid price required for continued listing ...
September 16, 2016XOMA’s 358 trial success indicates its lead in offering the therapy for widespread insulin-related abnormalities.
January 2, 2016In a new report, Wedbush analyst Liana Moussatos breaks down potential 2016 catalysts for every emerging pharmaceuticals ...